Moriwaki T, et al. - In patients with metastatic colorectal cancer (mCRC) who were refractory to standard chemotherapy, the efficacy of regorafenib and trifluridine/tipiracil (TFTD) were compared. For this group of patients, no significant difference in overall survival (OS) between regorafenib and TFTD was observed.

Methods

• Between June 2014 and September 2015, the clinical data of patients with mCRC who were treated with regorafenib or TFTD and those of drug-naive patients, were retrospectively collected from 24 institutions in Japan.
• Researchers used the Cox's proportional hazard models based on propensity score adjustment for baseline characteristics to assess the overall survival (OS).

Results

• The criteria was satisfied by a total of 550 patients (223 patients in the regorafenib group and 327 patients in the TFTD group).
• In the regorafenib group, the median OS was 7.9 months (95% confidence interval [CI], 6.8–9.2), and 7.4 months (95% CI, 6.6–8.3) in the TFTD group.
• In addition, the propensity score adjusted analysis showed that OS was similar between the two groups (adjusted hazard ratio [HR], 0.96; 95% CI, 0.78–1.18).
• They reported a significant interaction with age, in the subgroup analysis.
• In patients aged <65 years, regorafenib showed favorable survival (HR, 1.29; 95% CI, 0.98–1.69).
• On the other hand, TFTD was favored in patients aged ≥65 years (HR, 0.78; 95% CI, 0.59–1.03).